keyword
MENU ▼
Read by QxMD icon Read
search

BRVO

keyword
https://www.readbyqxmd.com/read/28503435/evaluation-of-hyperreflective-foci-as-a-prognostic-factor-of-visual-outcome-in-retinal-vein-occlusion
#1
Bin Mo, Hai-Ying Zhou, Xuan Jiao, Feng Zhang
AIM: To evaluate the potential role of hyperreflective foci (HF) as a prognostic indicator of visual outcome in patients with macular edema (ME) due to retinal vein occlusion (RVO). METHODS: We retrospectively reviewed 50 eyes of 50 patients with ME due to ischemic central retinal vein occlusion (CRVO), non-ischemic CRVO and branch retinal vein occlusion (BRVO) who were treated with anti-vascular endothelial growth factor (anti-VEGF) at Beijing Tongren Eye Center from January 2013 to July 2016...
2017: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/28496301/short-term-outcomes-in-patients-with-branch-retinal-vein-occlusion-who-received-intravitreal-aflibercept-with-or-without-intravitreal-ranibizumab
#2
Yoshihito Sakanishi, Ayumi Usui-Ouchi, Kazunori Tamaki, Keitaro Mashimo, Rei Ito, Nobuyuki Ebihara
PURPOSE: The purpose of this study was to determine the short-term outcomes for patients who received intravitreal aflibercept (IVA) with or without intravitreal ranibizumab (IVR) for macular edema (ME) due to branch retinal vein occlusion (BRVO). PATIENTS AND METHODS: Patients received IVA for ME due to BRVO. Patients who initially received IVA were defined as the treatment-naïve group and those who were switched from IVR to IVA after ME recurrence were defined as the switching group...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28489696/predictors-of-refractory-macular-edema-after-branch-retinal-vein-occlusion-following-intravitreal-bevacizumab
#3
Byung Gil Moon, Ah Ran Cho, You Na Kim, June-Gone Kim
PURPOSE: To evaluate the predictors of refractory macular edema (ME) that develops despite multiple bevacizumab injections in patients with branch retinal vein occlusion (BRVO). METHODS: A total of 107 patients who followed at least 2 years were assigned to 2 groups: a refractory group (n = 56) and a responsive group (n = 51). Baseline characteristics, treatment response at 3 months, and fluorescein angiographic findings at 6 months were compared. Then we tried to identify factors associated with refractory ME development...
May 9, 2017: Retina
https://www.readbyqxmd.com/read/28475051/predicting-macular-edema-recurrence-from-spatio-temporal-signatures-in-optical-coherence-tomography-images
#4
Wolf-Dieter Vogl, Sebastian M Waldstein, Bianca S Gerendas, Ursula Schmidt-Erfurth, Georg Langs
Prediction of treatment responses from available data is key to optimizing personalized treatment. Retinal diseases are treated over long periods and patients' response patterns differ substantially, ranging from a complete response to a recurrence of the disease and need for re-treatment at different intervals. Linking observable variables in high-dimensional observations to outcome is challenging. In this paper, we present and evaluate two different data-driven machine learning approaches operating in a high-dimensional feature space: sparse logistic regression and Random Forests based extra trees (ET)...
May 2, 2017: IEEE Transactions on Medical Imaging
https://www.readbyqxmd.com/read/28471106/comparison-of-ranibizumab-and-bevacizumab-for-macular-edema-associated-with-branch-retinal-vein-occlusion
#5
Bo Kwon Son, Hyung Woo Kwak, Eung Suk Kim, Seung Young Yu
PURPOSE: To assess the effectiveness and safety of intravitreal ranibizumab compared with bevacizumab for the treatment of macular edema associated with branch retinal vein occlusion (BRVO). METHODS: This was a retrospective study of 80 eyes with macular edema associated with BRVO. Patients received either 0.5 mg of ranibizumab (n = 24) or 1.25 mg of bevacizumab (n = 56) intravitreally. Both groups received three initial monthly injections followed by as-needed injections...
April 24, 2017: Korean Journal of Ophthalmology: KJO
https://www.readbyqxmd.com/read/28441077/comparison-of-conbercept-with-ranibizumab-for-the-treatment-of-macular-edema-secondary-to-branch-retinal-vein-occlusion
#6
Fengjiao Li, Ming Sun, Jianlian Guo, Aihua Ma, Bojun Zhao
PURPOSE: To confirm the therapeutic efficacy of conbercept for the treatment of macular edema (ME) secondary to branch retinal vein occlusion (BRVO). METHODS: In this prospective, randomized, and comparative study, patients were randomized and divided into conbercept (n = 18) and ranibizumab (n = 17) groups. After an initial intravitreal injection of either conbercept or ranibizumab, a pro re nata (PRN) strategy was adopted based on loss of visual acuity (VA) or increase in central macular thickness (CMT)...
April 25, 2017: Current Eye Research
https://www.readbyqxmd.com/read/28440254/combined-branch-retinal-vein-and-branch-retinal-artery-occlusion-clinical-features-systemic-associations-and-outcomes
#7
Sabyasachi Sengupta, Utsab Pan
PURPOSE: Retinal vascular occlusions affecting both the arterial and venous systems are rare events. Combined branch retinal artery (BRAO) and vein (BRVO) occlusion are exceedingly rare and not well characterized. METHODS: Six patients with combined BRAO and BRVO underwent a comprehensive eye examination, fundus fluorescein angiography, optical coherence tomography, and cardiovascular evaluation. RESULTS: Mean age at presentation was 54 ± 7...
March 2017: Indian Journal of Ophthalmology
https://www.readbyqxmd.com/read/28437483/quantitative-microvascular-analysis-of-retinal-venous-occlusions-by-spectral-domain-optical-coherence-tomography-angiography
#8
Nicole Koulisis, Alice Y Kim, Zhongdi Chu, Anoush Shahidzadeh, Bruce Burkemper, Lisa C Olmos de Koo, Andrew A Moshfeghi, Hossein Ameri, Carmen A Puliafito, Veronica L Isozaki, Ruikang K Wang, Amir H Kashani
PURPOSE: To quantitatively evaluate the retinal microvasculature in human subjects with retinal venous occlusions (RVO) using optical coherence tomography angiography (OCTA). DESIGN: Retrospective, cross-sectional, observational case series. PARTICIPANTS: Sixty subjects (84 eyes) were included (20 BRVO, 14 CRVO, 24 unaffected fellow eyes, and 26 controls). METHODS: OCTA was performed on a prototype, spectral domain-OCTA system in the 3x3mm central macular region...
2017: PloS One
https://www.readbyqxmd.com/read/28432581/comparison-of-immediate-versus-deferred-intravitreal-bevacizumab-in-macular-oedema-due-to-branch-retinal-vein-occlusion-a-pilot-study
#9
M A Khan, Varakutti Mallika, Dattakiran Joshi
PURPOSE: To compare visual and anatomical recovery of immediate versus deferred intravitreal Bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion (BRVO). METHODS: In a pilot study, 40 treatment naïve patients of branch retinal vein occlusion with macular oedema and vision 6/12 or less presenting within one month of onset were randomised into 2 groups (20 each) to receive either immediate intravitreal Bevacizumab or deferred (after 3 months of observation)...
April 21, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/28388705/retinal-microvasculature-and-visual-acuity-in-eyes-with-branch-retinal-vein-occlusion-imaging-analysis-by-optical-coherence-tomography-angiography
#10
Taku Wakabayashi, Tatsuhiko Sato, Chikako Hara-Ueno, Yoko Fukushima, Kaori Sayanagi, Nobuhiko Shiraki, Miki Sawa, Yasushi Ikuno, Hirokazu Sakaguchi, Kohji Nishida
Purpose: To investigate microvascular changes in the superficial capillary plexus (SCP) and deep capillary plexus (DCP) in eyes with resolved branch retinal vein occlusion (BRVO) and their association with best-corrected visual acuity (BCVA). Methods: Eighty-five eyes (82 consecutive patients) with BRVO after resolution of the macular edema were retrospectively evaluated. All patients underwent optical coherence tomography angiography (OCTA) for assessment of microvascular changes, including capillary telangiectasia, microaneurysm, and disruption of the foveal avascular zone (FAZ)...
April 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/28384724/gap-in-capillary-perfusion-on-optical-coherence-tomography-angiography-associated-with-persistent-macular-edema-in-branch-retinal-vein-occlusion
#11
Kotaro Tsuboi, Yuichiro Ishida, Motohiro Kamei
Purpose: To evaluate correlations between persistent macular edema associated with branch retinal vein occlusion (BRVO) and the macular perfusion status in the superficial capillary plexus (SCP) and deep capillary plexus (DCP) using optical coherence tomography angiography (OCTA). Methods: Retrospective, case-control study. Twenty patients with BRVO followed for 12 months or more were enrolled. Persistent macular edema was defined as central retinal thickness exceeding 300 μm that persisted or recurred less than 3 months after the final treatment...
April 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/28379652/quantitative-reduction-in-central-foveal-thickness-after-first-anti-vegf-injection-as-a-predictor-of-final-outcome-in-brvo-patients
#12
Rupak Roy, Kumar Saurabh, Avirupa Ghose, Dhileesh P Chandrasekharan, Preeti Sharma, Swakshyar Saumya Pal, Sudipta Das
PURPOSE: To analyze the predictive ability of quantitative reduction in central foveal thickness (CFT) after the first antivascular endothelial growth factor (anti-VEGF) injection to assess final outcome in branch retinal vein occlusion (BRVO) patients. DESIGN: A retrospective interventional consecutive case series. METHODS: We retrospectively reviewed 60 treatment-naive BRVO patients. All the patients were treated with bevacizumab injection pro re nata...
March 29, 2017: Asia-Pacific Journal of Ophthalmology
https://www.readbyqxmd.com/read/28367038/dexamethasone-intravitreal-implant-rescue-treatment-for-bevacizumab-refractory-macular-edema-secondary-to-branch-retinal-vein-occlusion
#13
Kyou Ho Lee, Eui Chun Kang, Hyoung Jun Koh
PURPOSE: To evaluate the prognostic factors and outcomes of dexamethasone intravitreal implant (DEX implant) for intravitreal bevacizumab refractory macular edema secondary to branch retinal vein occlusion (BRVO). METHODS: This was a retrospective, interventional case series. Medical records were reviewed, and a total of 38 eyes that were treated with DEX implant for macular edema secondary to BRVO that did not respond to at least two consecutive intravitreal bevacizumab injections (IBIs) were included...
April 2017: Korean Journal of Ophthalmology: KJO
https://www.readbyqxmd.com/read/28367036/natural-short-term-course-of-recurrent-macular-edema-following-intravitreal-bevacizumab-therapy-in-branch-retinal-vein-occlusion
#14
Su Jin Yoo, Jae Hui Kim, Tae Gon Lee, Jong Woo Kim, Sung Won Cho, Jung Il Han
PURPOSE: To evaluate the 3-month natural course of recurrent macular edema secondary to branch retinal vein occlusion (BRVO) treated with intravitreal bevacizumab. METHODS: This retrospective, observational study included 36 eyes with macular edema secondary to BRVO. All patients were initially treated with intravitreal bevacizumab for macular edema. Recurrence of macular edema was either not treated (untreated group) or treated with a single intravitreal bevacizumab injection (treated group)...
April 2017: Korean Journal of Ophthalmology: KJO
https://www.readbyqxmd.com/read/28365905/aflibercept-a-review-in-macular-oedema-secondary-to-branch-retinal-vein-occlusion
#15
Sheridan M Hoy
Aflibercept (Eylea(®)) is a fully human, recombinant fusion protein available in various countries worldwide, including those of the EU, as well as the USA, for intravitreal use in the treatment of macular oedema secondary to branch retinal vein occlusion (BRVO) in adults. Aflibercept acts as a soluble decoy receptor, binding with high affinity to vascular endothelial growth factor (VEGF)-A and placental growth factor (PIGF), preventing these angiogenic factors from binding to and activating their cognate receptors...
April 1, 2017: Drugs & Aging
https://www.readbyqxmd.com/read/28334720/intravitreal-dexamethasone-implant-versus-intravitreal-ranibizumab-for-the-treatment-of-macular-edema-secondary-to-retinal-vein-occlusion-in-a-chinese-population
#16
Xiaoya Gu, Xiaobing Yu, Shuang Song, Hong Dai
BACKGROUND: The aim of this work was to compare the efficacy of intravitreal dexamethasone implant (Ozurdex) and intravitreal ranibizumab (Lucentis) in the treatment of macular edema (ME) caused by retinal vein occlusion (RVO). METHODS: Thirty-two ME cases treated with Ozurdex and 32 ME cases treated with ranibizumab were enrolled, with 26 central (C)RVO and 6 branch (B)RVO subjects in each group. We compared the results of best-corrected visual acuity (BCVA), central retinal thickness, number of injections, and intraocular pressure (IOP) at 1, 2, 3, and 6 months after injection...
March 24, 2017: Ophthalmic Research
https://www.readbyqxmd.com/read/28316837/combination-of-navigated-macular-laser-photocoagulation-and-anti-vegf-therapy-precise-treatment-for-macular-edema-under-dry-retinal-conditions
#17
Ernest V Boiko, Dmitrii S Maltsev
Purpose. To compare the controllability of navigated macular laser photocoagulation (MLP) in dry versus edematous retina and validate that pretreatment diagnostic images can be used as basis for navigated MLP after the macular edema (ME) has been resolved. Materials and Methods. Group 1 was divided into subgroup 1 (dry retina MLP) and subgroup 2 (MLP in ME) for comparisons of laser-burn diameters. In group 2, the areas and locations of ME before an intravitreal injection of anti-VEGF (IVAV) were compared with those of recurrent ME...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/28315518/real-world-outcomes-of-anti-vegf-treatment-for-retinal-vein-occlusion-in-portugal
#18
Sara Vaz-Pereira, Inês P Marques, João Matias, Filipe Mira, Lígia Ribeiro, Rita Flores
PURPOSE: Retinal vein occlusion (RVO) is an important cause of visual disability in the modern world. We aim to evaluate the real-world outcomes of patients with RVO treated with anti-vascular endothelial growth factor (VEGF) in Portugal. METHODS: We performed a retrospective, observational, multicenter study including 8 centers across Portugal and 200 patients treated with either ranibizumab or bevacizumab. Data were collected at 3 time points: time of diagnosis (0 time point) and 6 and 12 months after initiating treatment...
February 28, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/28315513/increased-fibrinogen-to-albumin-ratio-in-ischemic-retinal-vein-occlusions
#19
Hande Guclu, Sadık A Ozal, Vuslat Pelitli Gurlu, Gülben Sayılan Özgün, Eray Özgün
PURPOSE: To demonstrate the relationship between ischemia and plasma fibrinogen and serum albumin levels in cases of retinal vein occlusion (RVO). METHODS: This study included 44 patients with central RVO (CRVO), 68 patients with branch RVO (BRVO), and 54 age- and sex-matched controls, for a total of 166 subjects. All of the subjects underwent full ophthalmologic examinations and complete physical examinations, including a detailed medical history and blood count, and biochemical parameters...
March 3, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/28288603/a-cute-angle-closure-attack-after-an-intravitreal-bevacizumab-injection-for-branch-retinal-vein-occlusion-a-case-report
#20
Seongyong Jeong, Min Sagong, Woohyok Chang
BACKGROUND: Intravitreal injection is widely used to treat retinal vein occlusion, and acute angle closure (AAC) is an exceptional complication of intravitreal injection. The authors report a case of AAC that occurred immediately after administering intravitreal bevacizumab to treat branch retinal vein occlusion (BRVO). CASE PRESENTATION: A 65-year-old woman was referred to the retina clinic of a tertiary referral center for the treatment of macular edema secondary to BRVO...
March 14, 2017: BMC Ophthalmology
keyword
keyword
44182
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"